ライフサイエンスコーパス: extensively drug-resistant

1 Of the 176 episodes of extensively drug-resistant A. baumannii bacteremia evalu

2 Breakthrough extensively drug-resistant A. baumannii bacteremia under

3 NG, PATIENTS, AND INTERVENTIONS: Adults with extensively drug-resistant A. baumannii bacteremia were

4 was to compare the outcomes of patients with extensively drug-resistant A. baumannii bacteremia, trea

5 ompared with colistin-carbapenem therapy for extensively drug-resistant A. baumannii bacteremia.

6 Extensively drug-resistant A. baumannii was defined as A

7 Since few therapeutic options exist for extensively drug resistant Acinetobacter baumannii, an e

8 Extensively drug-resistant Acinetobacter baumannii (XDR-

9 ania), 976 (75.1%) of which are multidrug or extensively drug resistant and 38.2%, 51.9%, and 36.3% o

10 The poor treatment outcomes for extensively drug-resistant and multidrug-resistant tuber

11 As a result, multidrug-resistant, extensively drug-resistant, and pandrug-resistant bacter

12 ity and death, especially infection from the extensively drug-resistant bacteria, A. baumannii.

13 lity of CRGNIs, particularly those caused by extensively drug-resistant bacteria.

14 The recent increase in extensively drug-resistant bacterial pathogens and the a

15 Conversely, 53% of extensively drug-resistant bloodstream CRGNIs at 2 of th

16 geting tuberculosis therapy, particularly in extensively drug-resistant disease for which current ant

17 g numbers of urinary tract infections due to extensively drug-resistant Gram-negative bacilli.

18 for efficacy against multidrug-resistant and extensively drug-resistant gram-negative rods.

19 but not L1 (metallo beta-lactamase) from the extensively drug resistant human pathogen Stenotrophomon

20 The emergence of multidrug-resistant and extensively drug-resistant isolates has prompted the nee

21 (13%) among MDR strains (particularly among extensively drug-resistant isolates, 5%), but was positi

22 nfection and the emergence of multidrug- and extensively drug-resistant (MDR and XDR, respectively) T

23 etting to investigate six cases of suspected extensively drug-resistant Mycobacterium tuberculosis (X

24 ly drug-resistant (XDR) tuberculosis and non-extensively drug-resistant (non-XDR) tuberculosis are de

25 bined CRE case information from the Illinois extensively drug-resistant organism registry with measur

26 Gram-negative bacteria showing multi-drug or extensively drug resistant phenotypes.

27 .1 y (34.4, 35.8) assuming patients with pre-extensively drug-resistant (PreXDR) and extensively drug

28 -1, BcII, and GOB-18) and, significantly, an extensively drug-resistant Stenotrophomonas maltophilia

29 th given the rise of multidrug resistant and extensively drug resistant strains of M. tuberculosis.

30 ographically diverse multidrug-resistant and extensively drug-resistant strains and could potentially

31 on 38 susceptible, multidrug-resistant, and extensively drug-resistant strains compared with convent

32 istent" state and inhibited the growth of 13 extensively drug-resistant strains of M. tuberculosis at

33 recent emergence of multidrug-resistant and extensively drug-resistant strains of Mycobacterium tube

34 acy, and are vulnerable to being overcome by extensively drug-resistant strains of Mycobacterium tube

35 osis cases caused by multidrug-resistant and extensively drug-resistant strains of Mycobacterium tube

36 The emergence of multidrug- and extensively drug-resistant strains of Mycobacterium tube

37 gainst six clinical isolates, which included extensively drug-resistant strains.

38 ent of patients with multidrug-resistant and extensively drug-resistant TB (M/XDR-TB).

39 gence of multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB) strains have furt

40 gence of multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB) strains.

41 ective cohort study of 172 subjects with MDR/extensively drug-resistant TB subjects and sequenced the

42 Extensively drug-resistant TB was defined as resistance

43 second-line injectable drugs, and not having extensively drug-resistant TB.

44 these drugs is a defining characteristic of extensively drug-resistant TB.

45 bly as the number of multidrug resistant and extensively drug resistant tuberculosis cases continues

46 Treatment of multidrug-resistant or extensively drug-resistant tuberculosis (DR-tuberculosis

47 echnologies for rapidly detecting multidrug-/extensively drug-resistant tuberculosis (M/XDR TB), but

48 The emergence of multi- and extensively drug-resistant tuberculosis (MDR-TB and XDR-

49 ultidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB) (M/XDR-

50 osocomial transmission has been described in extensively drug-resistant tuberculosis (XDR-TB) and HIV

51 Worldwide emergence of extensively drug-resistant tuberculosis (XDR-TB) has rai

52 terium tuberculosis (Mtb) have given rise to extensively drug-resistant tuberculosis (XDR-TB).

53 Extensively drug-resistant tuberculosis (XDR-tuberculosi

54 tivity against multidrug-resistant (MDR) and extensively drug-resistant tuberculosis and an excellent

55 We tested isolates from 651 patients for extensively drug-resistant tuberculosis and developed re

56 kers, and ethical and medicolegal aspects of extensively drug-resistant tuberculosis and other resist

57 We describe the management of extensively drug-resistant tuberculosis and treatment ou

58 Extensively drug-resistant tuberculosis can be cured in

59 The patients with extensively drug-resistant tuberculosis had undergone mo

60 ts with multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis has been noted,

61 Extensively drug-resistant tuberculosis has been reporte

62 t, management, and outcomes of patients with extensively drug-resistant tuberculosis in Tomsk, Russia

63 Extensively drug-resistant tuberculosis is a burgeoning

64 tuberculosis in these patients suggest that extensively drug-resistant tuberculosis may be acquired

65 f multidrug-resistant (MDR) tuberculosis and extensively drug-resistant tuberculosis poses a major th

66 Patients with extensively drug-resistant tuberculosis received daily,

67 eading frames in 240 multidrug-resistant and extensively drug-resistant tuberculosis strains and quan

68 e among patients with multidrug-resistant or extensively drug-resistant tuberculosis undergoing treat

69 None of the patients with extensively drug-resistant tuberculosis were coinfected

70 ly for patients with multidrug-resistant and extensively drug-resistant tuberculosis where prognosis

71 fore the diagnosis of 20 downstream cases of extensively drug-resistant tuberculosis with almost iden

72 esistance, including multidrug-resistant and extensively drug-resistant tuberculosis, might become le

73 ohort study, 273 South African patients with extensively drug-resistant tuberculosis, or resistance b

74 resistant tuberculosis, or resistance beyond extensively drug-resistant tuberculosis, were followed u

75 osols, and posed a threat of transmission of extensively drug-resistant tuberculosis.

76 ble for treating many cases of multidrug and extensively drug-resistant tuberculosis.

77 nts with multidrug-resistant tuberculosis or extensively drug-resistant tuberculosis.

78 roved cure rates for multidrug-resistant and extensively drug-resistant tuberculosis.

79 growing pandemic of multidrug-resistant and extensively drug-resistant tuberculosis.

80 Of the 651 patients tested, 48 (7.4%) had extensively drug-resistant tuberculosis; the remaining 6

81 development of multidrug resistant (MDR) and extensively drug resistant (XDR) forms of tuberculosis (

82 he analysis of multidrug resistant (MDR) and extensively drug resistant (XDR) Mtb strains that emerge

83 uberculosis and the more recent emergence of extensively drug resistant (XDR) tuberculosis are great

84 Extensively drug-resistant (XDR) Acinetobacter baumannii

85 of the few remaining therapeutic options for extensively drug-resistant (XDR) Gram-negative bacilli (

86 solates, 22 multidrug-resistant (MDR), and 1 extensively drug-resistant (XDR) M. tuberculosis strains

87 I >/= 16000), multidrug-resistant (MDR), and extensively drug-resistant (XDR) Mycobacterium tuberculo

88 erapy, and outcomes of bacteremia because of extensively drug-resistant (XDR) Pseudomonas aeruginosa

89 TB), including multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains.

90 of cases of multidrug-resistant (MDR) TB and extensively drug-resistant (XDR) TB in South Africa like

91 pre-extensively drug-resistant (PreXDR) and extensively drug-resistant (XDR) TB received bedaquiline

92 TB, including multidrug-resistant (MDR) and extensively drug-resistant (XDR) TB, is no longer restri

93 , particularly multidrug-resistant (MDR) and extensively drug-resistant (XDR) TB.

94 Multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB) are n

95 Extensively drug-resistant (XDR) tuberculosis (TB) canno

96 xemplified by the largest global outbreak of extensively drug-resistant (XDR) tuberculosis (TB) ident

97 Treating extensively drug-resistant (XDR) tuberculosis (TB) is a

98 The emergence of multidrug-resistant and extensively drug-resistant (XDR) tuberculosis (TB) is a

99 Extensively drug-resistant (XDR) tuberculosis (TB), whic

100 ces, and treatment outcomes of patients with extensively drug-resistant (XDR) tuberculosis and non-ex

101 Multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis are emergi

102 l outbreaks of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis are increa

103 treatment-related outcomes in patients with extensively drug-resistant (XDR) tuberculosis are unknow

104 Multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis continue t

105 r multidrug-resistant (MDR) tuberculosis and extensively drug-resistant (XDR) tuberculosis depends up

106 e emergence of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis during the

107 In the past 8 years, extensively drug-resistant (XDR) tuberculosis has emerge

108 and spread of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis has led to

109 Extensively drug-resistant (XDR) tuberculosis has spread

110 Multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis have emerg

111 rugs for use in multidrug-resistant (MDR) or extensively drug-resistant (XDR) tuberculosis have focus

112 widespread multiple-drug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis have raise

113 onsequences of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis in a rural

114 Extensively drug-resistant (XDR) tuberculosis is becomin

115 The prevalence of extensively drug-resistant (XDR) tuberculosis is increas

116 A widespread epidemic of extensively drug-resistant (XDR) tuberculosis is occurri

117 prevalence of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis was 12.6%

118 The proportion of MDR cases with extensively drug-resistant (XDR) tuberculosis was 16% ov

119 Nineteen (54%) had extensively drug-resistant (XDR) tuberculosis, and 14 (4

120 d of multidrug-resistant (MDR) tuberculosis, extensively drug-resistant (XDR) tuberculosis, and more

121 le for kanamycin A resistance, a hallmark of extensively drug-resistant (XDR) tuberculosis, in a larg

122 tly needed for multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis, which are

123 On multivariable analysis that adjusted for extensively drug-resistant (XDR) tuberculosis-MDR tuberc

124 sing burden of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis.

125 uiline is especially likely in patients with extensively drug-resistant (XDR) tuberculosis.